Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects.

Front Immunol · 2026 · PMC13233420 · PMID 42254025

Europe PMC DOI

hedged sentence

0.1760

closest p · 3.5× alpha

0.1760

boldest claim

The sentences

did not reach statistical significanceP = 0.176not close (p > 0.1)

Conversely, although a reduction in growth rate was observed in the UMSCC47 model, the difference did not reach statistical significance (P = 0.176).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.